BriaCell announces survival data from its Phase 2 study of Bria-IMT

BriaCell (BCTX) Therapeutics announces new positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors, outperforming ADC drugs in hormone receptor positive metastatic breast cancer patients. In BriaCell’s Phase 2 clinical study in late-stage MBC, 25 of 37 patients treated with the ongoing pivotal Phase 3 Bria-IMT formulation were identified as having HR+ breast cancer. The survival data of these 25 patients exceeds those of the current ADC standard of care TRODELVY. The survival data for the Bria-IMT regimen + immune check point inhibitor in the triple negative breast cancer, characterized by the absence of estrogen, progesterone and human epidermal growth factor receptors, was similar to TRODELVY but still markedly higher than those of chemotherapy.